Results 101 to 110 of about 470,131 (305)

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta   +6 more
wiley   +1 more source

Role of minimal residual disease assessment in multiple myeloma

open access: yesHaematologica
Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells. MM is a heterogeneous disease, featured by various molecular subtypes with different outcomes. With the advent of very efficient therapies including
Raphael Szalat   +2 more
doaj   +1 more source

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia

open access: yesHaematologica, 2019
A high proportion of patients with acute myeloid leukemia who achieve minimal residual disease negative status ultimately relapse because a fraction of pathological clones remains undetected by standard methods.
Esther Onecha   +21 more
doaj   +1 more source

Therapeutic Apheresis for Intravenous Methylprednisolone‐Refractory Neuromyelitis Optica Spectrum Disorder: Clinical and Radiological Outcomes in a Single‐Center Case Series

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing autoimmune disease of the central nervous system. High‐dose intravenous methylprednisolone (IVMP) is the standard first‐line therapy for acute attacks, although some patients remain refractory.
Wataru Horiguchi   +5 more
wiley   +1 more source

How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet

open access: yesHaematologica, 2009
Resistance to therapeutic agents is a major factor in the failure of cancer treatments. In leukemia, the resistant cells remaining in the bone marrow and/or peripheral blood constitute minimal residual disease and are detectable by highly sensitive ...
Marie C. Béné, Jaspal S. Kaeda
doaj   +1 more source

Magnetic resonance imaging for localization of prostate cancer in the setting of biochemical recurrence [PDF]

open access: yes, 2016
The clinical suspicion of local recurrence of prostate cancer after radical treatment is based on the onset of biochemical failure. The use of multiparametric magnetic resonance imaging (MRI) for prostate cancer has increased over recent years, mainly ...
Barchetti, Flavio   +6 more
core   +1 more source

There is nothing minimal about residual disease [PDF]

open access: yesBlood, 2018
Can the detection of measurable residual disease (MRD) become the standard approach for acute lymphoblastic leukemia (ALL)? In this issue of Blood,Wood et al1 use a highly sensitive sequencing approach that is an improvement on conventional methods by both performance characteristics and potential for standardization.
openaire   +2 more sources

Infection Control Practices for Vascular Access Management in Hemodialysis: Results From a Nationwide Survey of Japanese National University Hospitals

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction Bloodstream infections due to repeated vascular access (VA) puncture and circuit connections remain major concerns in hemodialysis. Therefore, we examined current practices for glove, disinfectant, and personal protective equipment (PPE) use according to VA type in national university hospitals in Japan.
Aiko Yamada   +6 more
wiley   +1 more source

Assessment of minimal residual disease in childhood acute lymphoblastic leukemia

open access: yesJournal of Applied Hematology, 2016
The improving cure rate of childhood acute lymphoblastic leukemia (cALL) is considered as success story in the field of oncology. It has become possible due to progressive refinement of treatment over the period of years.
Sonia K Parikh, Urmila P Uparkar
doaj   +1 more source

Modulator Therapy for Cystic Fibrosis: An Exploration of Current Research [PDF]

open access: yes, 2020
Developing a drug therapy that addresses the root cause of cystic fibrosis (CF) by increasing CFTR protein levels has long been a research challenge. After genetic therapy failed because a suitable delivery system could not be found, researchers began ...
Rombocos, Jessalyn
core   +1 more source

Home - About - Disclaimer - Privacy